A brief introduction to palbociclib/palbociclib

Palbociclib (Palbociclib), trade name: Ibrance, is an oral inhibitor of cyclin-dependent kinases (CDKs) 4 and 6. This drug plays a key role in the cell cycle because of its ability to trigger cell cycle progression.

Pabociclib has been approved in the United States for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. It is often used in combination with aromatase inhibitors as initial endocrine therapy in postmenopausal women.

In vitro studies have shown that palbociclib has the potential to reduce cell proliferation in estrogen receptor-positive breast cancer cell lines by inhibiting cell cycle progression from G1 to S phase. This study demonstrates that with the expression of RB1 and CCND1 and the low expression of CDKN2A, the sensitivity of cells increases significantly. Furthermore, palbociclib in combination with antiestrogen enhanced in vivo antitumor activity in a mouse model of estrogen receptor-positive breast cancer.

Clinical trials show that the combination of palbociclib and letrozole can significantly improve progression-free survival (PFS) in patients with metastatic breast cancer who have not received endocrine therapy. (PFS). The results showed that PFS increased from 4.5 months to 9.5 months, with an overall response rate (ORR) of 24.6%.

Overall, palbociclib, as an innovative targeted therapy, plays an important role in the treatment of breast cancer. However, like other medications, it may cause some side effects, so use it with caution and follow your doctor's advice.